Home » Stocks » XCUR

Exicure, Inc. (XCUR)

Stock Price: $1.51 USD -0.07 (-4.43%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 131.72M
Revenue (ttm) 14.87M
Net Income (ttm) -18.96M
Shares Out 87.23M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $1.51
Previous Close $1.58
Change ($) -0.07
Change (%) -4.43%
Day's Open 1.55
Day's Range 1.50 - 1.64
Day's Volume 141,626
52-Week Range 0.96 - 3.84

More Stats

Market Cap 131.72M
Enterprise Value 45.94M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 87.23M
Float 58.76M
EPS (basic) -0.27
EPS (diluted) -0.24
FCF / Share -0.14
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 986,789
Short Ratio 4.05
Short % of Float 1.68%
Beta 1.47
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 8.86
PB Ratio 1.72
Revenue 14.87M
Operating Income -19.91M
Net Income -18.96M
Free Cash Flow -12.52M
Net Cash 85.78M
Net Cash / Share 0.98
Gross Margin -121.37%
Operating Margin -133.93%
Profit Margin -127.50%
FCF Margin -84.19%
ROA -21.39%
ROE -40.71%
ROIC -44.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$10.50*
(595.36% upside)
Low
7.00
Current: $1.51
High
18.00
Target: 10.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue1.300.129.721.04
Revenue Growth998.31%-98.79%838.13%-
Gross Profit1.300.129.721.04
Operating Income-26.62-21.82-10.41-16.16
Net Income-26.30-22.41-11.01-16.94
Shares Outstanding57.6741.1910.120.11
Earnings Per Share-0.46-0.54-1.09-149.37
Operating Cash Flow1.32-19.49-19.79-5.05
Capital Expenditures-1.08-0.09-0.93-0.39
Free Cash Flow0.24-19.58-20.72-5.44
Cash & Equivalents11126.2725.7619.62
Total Debt4.974.934.865.67
Net Cash / Debt10621.3420.9113.96
Assets11528.7628.9920.58
Liabilities34.527.809.0118.13
Book Value80.7520.9519.982.45
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Exicure, Inc.
Country United States
Employees 47
CEO David A. Giljohann

Stock Information

Ticker Symbol XCUR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: XCUR

Description

Exicure, a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes AST-008 that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA?based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; and XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; and license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome. The company was founded in 2011 and is based in Chicago, Illinois.